ASCO 2024 | PROs from TROPION-Breast01: datopotamab deruxtecan in HR+/HER2- breast cancer

Sonia Pernas, MD, PhD, Catalan Institute of Oncology, Catalan, Spain, discusses patient-reported outcomes (PROs) from the Phase III TROPION-Breast01 study (NCT05104866) of datopotamab deruxtecan versus investigator’s choice of chemotherapy in patients with inoperable or metastatic HR+/HER2- breast cancer. The PRO findings, in terms of physical functioning and pain, support datopotamab deruxtecan as a promising, well-tolerated treatment option with manageable safety for this patient population. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.